SOAT1 and acute lymphoblastic leukemia: The part 2/efficacy phase of the study involves evaluating whether the addition of ruxolitinib to the standard of care in high-risk B-ALL chemotherapy backbone may improve outcomes for children and AYAs with Ph-like ALL harboring JAK/STAT pathway lesions, with results anticipated in 2026.